搜索
Lyell Immunopharma Inc
LYEL添加自选
17.920USD
-1.100-5.78%
收盘 05/15, 16:00（美东）报价延迟15分钟
418.15M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.78%
5天
-7.29%
1月
-24.39%
6月
+5.85%
今年开始到现在
-41.78%
1年
+115.90%
TradingKey Lyell Immunopharma Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Lyell Immunopharma Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名85/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价42.20。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Lyell Immunopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Lyell Immunopharma Inc亮点
亮点风险
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
业绩增长期
公司处于发展阶段，最新年度总收入36.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入36.00K美元
估值合理
公司最新PE估值-1.32，处于3年历史合理位
机构加仓
最新机构持股13.43M股，环比增加12.34%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值39.49K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.01
分析师目标
根据
6
位分析师
买入
评级
42.200
目标均价
+121.87%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Lyell Immunopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Lyell Immunopharma Inc简介
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
公司代码LYEL
公司Lyell Immunopharma Inc
CEOSeely (Lynn)
网址https://lyell.com/
相关品种
